Join us for this two-day meeting, a collaboration between RSM Nephrology and Kidney Research UK Glomerulonephritis (GN) Clinical Study Group (CSG), showcasing developments in the field of inflammatory renal disease, advancements in basic science, registries, therapeutic targets and clinical trials in glomerulonephritis.
By attending the meeting, participants will gain an in-depth understanding on the pathological mechanisms and therapeutic targets in Glomerulonephritis. Topics will be reviewed and delivered through interactive lectures, case based and panel discussions.
This meeting is a collaboration between scientists, clinicians, trialist and pharm showcasing pioneering developments in inflammatory renal diseases.
By attending the meeting, you will:
- Gain an increased awareness of developments in refining definitions of disease entities in inflammatory renal diseases
- Understand the pathological mechanisms and therapeutic targets in Glomerulonephritis
- Enhance your knowledge of management strategies for Glomerulonephritis
- Be aware of developments in techniques in identifying renal autoimmune diseases
- Understand the pathological mechanisms and therapeutic targets in Glomerulonephritis
- Gain updates on UK Kidney Research GN Clinical study Group
Follow us on:
Facebook
Instagram
LinkedIn
Twitter
YouTube
We would like to thank our sponsors AstraZeneca, CSL Vifor, Novartis and Thornton & Ross STADA Group who have provided sponsorship towards this independent Programme.
This activity has also been supported by Alentis Therapeutics, Alpine Immune Sciences, argenx, Arrowhead Pharmaceutical, Dimerix, Otsuka, Roche and Vera Therapeutics in the form of educational grants.
The companies listed above have had no editorial input into or control over the agenda, content development or choice of speakers for the event.
Due to this funding, the Nephrology Section is pleased to offer this event at a subsidised fee for participants.